31
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Puerarin attenuates angiotensin II-induced cardiac fibroblast proliferation via the promotion of catalase activity and the inhibition of hydrogen peroxide-dependent Rac-1 activation

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The aims of the present study were to evaluate the effects of puerarin on angiotensin II-induced cardiac fibroblast proliferation and to explore the molecular mechanisms of action. Considering the role of H 2O 2 in nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation, we hypothesized that modulating catalase activity would be a potential target in regulating the redox-sensitive pathways. Our results showed that the activation of Rac1 was dependent on the levels of intracellular H 2O 2. Puerarin blocked the phosphorylation of extracellular regulated protein kinases (ERK)1/2, abolished activator protein (AP)-1 binding activity, and eventually attenuated cardiac fibroblast proliferation through the inhibition of H 2O 2-dependent Rac1 activation. Further studies revealed that angiotensin II treatment resulted in decreased catalase protein expression and enzyme activity, which was disrupted by puerarin via the upregulation of catalase protein expression at the transcriptional level and the prolonged protein degradation. These findings indicated that the anti-proliferation mechanism of puerarin was mainly through blocking angiontensin II-triggered downregu-lation of catalase expression and H 2O 2-dependent Rac1 activation.

          Author and article information

          Journal
          CJNM
          Chinese Journal of Natural Medicines
          Elsevier
          1875-5364
          20 January 2018
          : 16
          : 1
          : 41-52
          Affiliations
          [1] 1Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China
          Author notes
          *Corresponding author: LIU Li-Hong, Tel: 86-10-85231631, Fax: 86-10-85231786, E-mail: hongllh@ 123456126.com

          These authors have no conflict of interest to declare.

          Article
          S1875-5364(18)30028-1
          10.1016/S1875-5364(18)30028-1
          29425589
          97f31a71-9da6-4e5a-b4ea-5c2fa4a544e6
          Copyright © 2018 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.
          History
          : 11 May 2017
          Funding
          Funded by: National S&T Major Special Project on Major New Drug Innovation
          Award ID: 2012ZX09301002-001-015
          Funded by: National Natural Science Foundation of China
          Award ID: 30772284
          The work was supported by the National S&T Major Special Project on Major New Drug Innovation (No. 2012ZX09301002-001-015) and the National Natural Science Foundation of China (No. 30772284).

          Medicine,Pharmaceutical chemistry,Pharmacology & Pharmaceutical medicine,Complementary & Alternative medicine
          Angiontensin II,Puerarin,Catalase,Hydrogen peroxide

          Comments

          Comment on this article